Logo

AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Receives the CHMP’s Positive Opinion for 1L Mantle Cell Lymphoma (MCL)

Share this
AstraZeneca

AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Receives the CHMP’s Positive Opinion for 1L Mantle Cell Lymphoma (MCL)

Shots:

  • The CHMP has recommended Calquence + bendamustine & rituximab for the treatment of 1L MCL adults, who are ineligible for autologous HSCT; regulatory review is ongoing in Japan & other regions
  • Opinion was based on P-III (ECHO) trial assessing the combination vs SoC (bendamustine & rituximab) in 1L MCL pts (≥65yrs.; n=635), which showed improved PFS of 27%, with mPFS of 66.4 vs 49.6mos.; data was presented at EHA 2024
  • Calquence (BTK inhibitor, BID, PO) is being evaluated as a monotx. & in combination with SoC chemoimmunotherapy for multiple B-cell blood cancers, incl. CLL, MCL & diffuse LBCL

Ref: AstraZeneca | Image: AstraZeneca

Related News:- AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Ridhi Rastogi

Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions